Jun. 23, 2021	Teijin Receives Additional Approval in Japan for Merz’s Xeomin® Botulinum Toxin Type A
Apr. 01, 2021	Notice Regarding Completion of Transfer of Japan Sales of Type 2 Diabetes Treatments
Mar. 23, 2021	Teijin to Commence Manufacture and Sale in Japan of Abaloparatide Acetate as Treatment for Osteoporosis
Feb. 26, 2021	Notice Regarding Execution of Asset Transfer Agreement for Transfer of Japan Sales, Intellectual Properties, and Manufacturing and Marketing Approval of Type 2 Diabetes Treatments (Nesina®, Liovel®, Inisync®, and Zafatek®)

Page Top